Exousia Pro Announces Strategic Acquisition to Launch a New Telehealth Division
Exousia Pro (OTCPINK:MAJI) announced its strategic entry into the telehealth market through an acquisition that will establish its new division, Exousia Health. The acquired telehealth company brings an initial base of 1,000 active clients and projected monthly revenue of $50,000.
The company is reviewing two additional significant contracts expected to boost monthly revenue substantially. Exousia Health also plans to integrate a compounding pharmacy operation, creating a third revenue stream by handling prescriptions from its telehealth doctors directly.
Management expects Exousia Health to become the company's primary revenue generator until its AI division begins licensing cancer therapy technology.
Exousia Pro (OTCPINK:MAJI) ha annunciato il suo ingresso strategico nel mercato della telemedicina tramite un’acquisizione che darà vita alla nuova divisione, Exousia Health. L’azienda acquisita porta con sé una base iniziale di 1.000 clienti attivi e un fatturato mensile previsto di $50.000.
La società sta valutando due contratti aggiuntivi di rilievo che dovrebbero incrementare in modo significativo i ricavi mensili. Exousia Health prevede inoltre di integrare un’attività di farmacia galenica, creando una terza fonte di ricavo gestendo direttamente le prescrizioni dei medici telematici.
La direzione si aspetta che Exousia Health diventi il principale generatore di ricavi dell’azienda fino a quando la divisione AI non inizierà a concedere in licenza la tecnologia per terapie oncologiche.
Exousia Pro (OTCPINK:MAJI) anunció su entrada estratégica en el mercado de la telemedicina mediante una adquisición que dará origen a su nueva división, Exousia Health. La empresa adquirida aporta una base inicial de 1.000 clientes activos y unos ingresos mensuales proyectados de $50,000.
La compañía está revisando dos contratos adicionales importantes que se espera aumenten considerablemente los ingresos mensuales. Exousia Health también planea integrar una farmacia de preparación (“compounding”), creando una tercera fuente de ingresos al manejar directamente las recetas de sus médicos de telemedicina.
La dirección espera que Exousia Health se convierta en la principal generadora de ingresos de la compañía hasta que su división de IA comience a licenciar la tecnología para terapias contra el cáncer.
Exousia Pro (OTCPINK:MAJI)는 인수로 원격의료(텔레헬스) 시장에 전략적으로 진출하여 새로운 사업부 Exousia Health를 설립한다고 발표했습니다. 인수한 텔레헬스 업체는 1,000명의 활성 고객과 월 예상 매출 $50,000을 보유하고 있습니다.
회사는 월 매출을 크게 늘릴 것으로 예상되는 두 건의 추가 대형 계약을 검토 중입니다. Exousia Health는 또한 조제약국(compounding pharmacy) 운영을 통합해 원격의료 의사의 처방을 직접 처리하는 세 번째 수익원을 마련할 계획입니다.
경영진은 Exousia Health가 인공지능(AI) 부문이 암 치료 기술의 라이선스를 시작할 때까지 회사의 주요 수익 창출원이 될 것으로 기대하고 있습니다.
Exousia Pro (OTCPINK:MAJI) a annoncé son entrée stratégique sur le marché de la télésanté via une acquisition qui créera sa nouvelle division, Exousia Health. La société acquise apporte une base initiale de 1 000 clients actifs et un chiffre d’affaires mensuel prévisionnel de 50 000 $.
L’entreprise examine deux autres contrats importants qui devraient augmenter sensiblement les revenus mensuels. Exousia Health prévoit également d’intégrer une pharmacie de préparation (compounding), créant ainsi une troisième source de revenus en gérant directement les prescriptions de ses médecins en télémédecine.
La direction s’attend à ce qu’Exousia Health devienne le principal générateur de revenus de la société jusqu’à ce que la division IA commence à concéder sous licence la technologie de thérapies contre le cancer.
Exousia Pro (OTCPINK:MAJI) hat seinen strategischen Eintritt in den Telemedizinmarkt durch eine Übernahme angekündigt, die die neue Sparte Exousia Health begründen wird. Das erworbene Telemedizinunternehmen bringt eine Anfangsbasis von 1.000 aktiven Kunden und einen prognostizierten Monatsumsatz von $50.000 mit.
Das Unternehmen prüft zwei weitere bedeutende Verträge, die die monatlichen Einnahmen voraussichtlich deutlich steigern werden. Exousia Health plant zudem, eine Rezepturapotheke (compounding pharmacy) zu integrieren und dadurch eine dritte Einnahmequelle zu schaffen, indem es die Rezepte der Telemedizin-Ärzte direkt abwickelt.
Das Management erwartet, dass Exousia Health die wichtigste Einnahmequelle des Unternehmens wird, bis die KI-Sparte beginnt, die Technologie für Krebstherapien zu lizenzieren.
- Immediate revenue generation of $50,000 monthly from 1,000 active clients
- Two additional significant contracts under review for revenue expansion
- Three diversified revenue streams: telehealth consultations, prescribed regimens, and compounding pharmacy
- Strategic entry into the rapidly growing telehealth market
- 12-month timeline for contract implementation indicates slow revenue ramp-up
- Revenue dependency on telehealth division until AI technology commercialization
- Acquisition completion still pending and subject to closing conditions
Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately
ORLANDO, FL / ACCESS Newswire / September 8, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused on exosome-based therapies, today announced that it expects to enter into the rapidly growing telehealth market, following its agreement to acquire a telehealth company, which will serve as the foundation of a new division, Exousia Health. Completion of this acquisition is a key step in diversifying the company's future revenue streams.
Following the acquisition closing, Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately
Exousia Health is also in the final stages of a due diligence review of two additional, significant contracts, which are expected to substantially increase monthly revenue. These contracts would generate revenue from both patient-doctor consultations and the markup on doctor-prescribed regimens.
"The telehealth market is experiencing rapid expansion, and this acquisition positions us to be a key player," said Matt Dwyer, President of Exousia Pro, Inc. "We project significant month-over-month revenue growth for Exousia Health, with the two large contracts being onboarded over 12 months to ensure a seamless transition for clients. This methodical approach will enable us to scale our operations effectively. We anticipate that Exousia Health will be our primary revenue driver, until Exousia AI begins to license its cancer therapy technology."
Mr. Dwyer added that the launch of Exousia Health is expected to include a third, synergistic revenue stream - the addition of a compounding pharmacy to its operations, allowing Exousia Health doctors to submit patient prescriptions directly to the company's pharmacy, thereby capturing additional revenue.
About the Telehealth Market
The telehealth market is a major sector of the global economy, with a projected market size exceeding
About Us
Exousia Pro (formerly Marijuana, Inc.) is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Exousia Pro, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
SOURCE: Exousia Pro, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the expected monthly revenue for Exousia Pro's (MAJI) new telehealth division?
How many active clients will Exousia Pro's (MAJI) telehealth division have at launch?
What are the revenue streams for Exousia Pro's (MAJI) new telehealth division?
How long will it take Exousia Pro (MAJI) to implement its new telehealth contracts?
What is Exousia Pro's (MAJI) strategy for the telehealth division expansion?
